Evotec (NASDAQ:EVO) Shares Gap Up – Should You Buy?

Evotec SE (NASDAQ:EVO)’s share price gapped up prior to trading on Monday . The stock had previously closed at $4.49, but opened at $4.82. Evotec shares last traded at $4.78, with a volume of 11,147 shares traded.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Jefferies Financial Group downgraded shares of Evotec from a “buy” rating to a “hold” rating and decreased their target price for the company from $8.70 to $3.80 in a research note on Monday, October 7th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Evotec in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. Finally, Morgan Stanley downgraded shares of Evotec from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $15.00 to $6.00 in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.93.

Evotec Stock Performance

The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The stock’s 50 day simple moving average is $3.83 and its 200 day simple moving average is $4.19.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in EVO. Cetera Advisors LLC bought a new position in Evotec during the 1st quarter valued at $188,000. Vanguard Personalized Indexing Management LLC bought a new position in Evotec during the 2nd quarter valued at $87,000. DCF Advisers LLC boosted its stake in Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after acquiring an additional 67,156 shares during the last quarter. Novo Holdings A S bought a new position in Evotec during the 2nd quarter valued at $71,183,000. Finally, Mediolanum International Funds Ltd bought a new position in Evotec during the 3rd quarter valued at $512,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.